Targeting Wnt Signaling Pathway in Cancer Therapeutics

The Wnt signalling pathway orchestrates cell proliferation, differentiation and survival through a cascade that culminates in nuclear transcriptional activation. Aberrant Wnt activity is implicated across a spectrum of malignancies, notably colorectal, breast and synovial sarcomas, where mutations in pathway components drive uncontrolled growth and metastatic potential. Therapeutic efforts span extracellular blockade of ligand–receptor interactions, destabilisation of cytoplasmic β-catenin and disruption of nuclear transcriptional complexes. Small-molecule inhibitors, monoclonal antibodies and emerging protein degraders have advanced into preclinical models and early-phase trials, revealing both efficacy against cancer stemness and challenges of on-target toxicity in normal tissues. Precision strategies guided by biomarkers such as RNF43 mutations, RSPO fusions and TNIK amplification promise to refine patient selection. Integration of structural biology, chemical genetics and translational oncology is critical to translate pathway modulators into safe and effective anticancer agents.

Research from Nature Portfolio

Recent studies have identified Traf2- and Nck-interacting kinase (TNIK) as a key co-activator within the β-catenin–TCF4 transcriptional complex and demonstrated the therapeutic impact of its inhibition. The first orally available TNIK inhibitor, NCB-0846, binds the ATP site in an inactive kinase conformation, suppresses sphere-forming capacity of colorectal cancer stem cells and inhibits tumourigenesis in Apcmin/+ mouse models. In parallel, drug-repurposing efforts using computational modelling and screening of approved compounds uncovered that mebendazole selectively binds and inhibits TNIK at micromolar concentrations, offering a promising avenue for rapid clinical translation due to established safety profiles.

Targeting Wnt Signaling Pathway in Cancer Therapeutics publication trend

The graph below shows the total number of articles in targeting wnt signaling pathway in cancer therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Wnt signalling pathway: A conserved cell-to-cell communication cascade regulating development, homeostasis and stem cell renewal.

β-catenin: A dual-function protein that mediates cell adhesion at the membrane and acts as a transcriptional co-activator in the nucleus.

TNIK (Traf2- and Nck-interacting kinase): A serine/threonine kinase that interacts with β-catenin–TCF complexes to drive Wnt target gene expression.

Epithelial–mesenchymal transition (EMT): A cellular programme enabling epithelial cells to acquire migratory and invasive properties critical for metastasis.

References

1. Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduction and Targeted Therapy (2021).
2. TNIK inhibition abrogates colorectal cancer stemness. Nature Communications (2016).
3. Comprehensive Modeling and Discovery of Mebendazole as a Novel TRAF2- and NCK-interacting Kinase Inhibitor. Scientific Reports (2016).
4. Structural Insight into TNIK Inhibition. International Journal of Molecular Sciences (2022).
5. Feasibility of Targeting Traf2-and-Nck-Interacting Kinase in Synovial Sarcoma. Cancers (2020).
6. Pharmacological blockage of transforming growth factor-β signalling by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846. British Journal of Cancer (2020).